Q2 FY2026 EarningsQ2 FY26 results beat consensus across most key financial metrics, with revenue of $5.44B slightly exceeding the $5.37B expected and normalized EPS of $0.86 topping the $0.83 mean estimate. Gross margin was a significant highlight at 70.7%, beating the 70.1% consensus driven by recovery of previously incurred tariffs and product mix. While the Cardiovascular segment outperformed with 8.3% reported growth led by Farapulse™, the Urology business saw stagnation due to China VBP headwinds and commercial disruption.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Boston Scientific(BSX) the Revenue is 5.442 B (+7.53%), Beat estimate;the EBIT is 1.543 B (+10.29%), Beat estimate;the EPS is 0.61 (+15.09%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
5.44B7.53%
5.37B6.03%
+0.08B1.50%
EBITExceed expectations
1.54B10.29%
1.52B8.33%
+0.03B1.96%
EPSExceed expectations
0.6115.09%
0.605214.18%
+0.00480.91%
Upcoming earnings report - FY2026 Q3 Earning Release
Available dateOct 28, 2026
Estimate Revenue5.257 B
Estimate EBIT1.47 B
Estimate EPS0.5716
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf